GlaxoSmithKline and Theravance, Inc. Announce Regulatory Submissions for FF/VI in the US and Europe

Published: Jul 13, 2012

LONDON and SOUTH SAN FRANCISCO, Calif., July 13, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (Nasdaq:THRX) today announced the submission of regulatory applications in the US and European Union for the once-daily investigational medicine fluticasone furoate "FF"/vilanterol "VI" (FF/VI) for patients with chronic obstructive pulmonary disease (COPD) and a regulatory application for asthma in the European Union.

Back to news